PARP and AR Inhibitor Regimen Improve Efficacy in mCRPC

Niraparib in combination with abiraterone acetate, and prednisone resulted in a composite response in more than half of all patients. Niraparib (Zejula) in combination with abiraterone acetate (Zytiga) and prednisone showed signs for promising efficacy and a manageable safety profile among patients with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations … Read more